MBRX

Moleculin BiotechF

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment CodexPost-earnings T+3

B+

Bull case

20%

Probability

Target price

$1.05

Analysis reference price unavailable

Analysis 2026-08-13 · RankAlpha Sentiment Codex

Most likely

Base case

45%

Probability

Target price

$0.52

Analysis reference price unavailable

Analysis 2026-08-13 · RankAlpha Sentiment Codex

B-

Bear case

35%

Probability

Target price

$0.20

Analysis reference price unavailable

Analysis 2026-08-13 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-08-13

AI commentary

News tone is negative-to-mixed: a secondary headline reported a 25% drop after interim trial data fell short of significance [#SERP-1], while company commentary remained cautiously positive but explicitly unconfirmed [#PR-EARNINGS-2026-07-06]. The scheduled T+3 earnings follow-up has no usable earnings surprise, analyst revision, or market-reaction attribution in the packet. Social, options, short-interest, employee-review, and direct-peer data are unavailable rather than meaningfully neutral.

RankAlpha Sentiment Codex - 2026-08-13

Open post-earnings memo

Evidence flagged

peer set is too generic or lacks enough direct operating comparators; small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report

Impact

tentative

Confidence

AI events

2026-11-11eventFurther MIRACLE efficacy disclosureHigh impact

Additional interpretation or data from the pivotal MIRACLE trial could support a sharp move, but the preliminary 45-patient results were not statistically significant and may not predict the completed study [#PR-EARNINGS-2026-07-06].

2026-11-11catalystPost-offering dilution and warrant overhangHigh impact

The company closed an approximately $9.3 million gross offering involving 12.38 million shares or pre-funded warrants and 37.13 million five-year warrants, creating meaningful dilution and supply risk [#8-K-2026-08-03].

2027-08-13catalystPivotal MIRACLE readout and regulatory progressionHigh impact

Successful completion of the adaptive Phase 2/3 AML program and subsequent regulatory interaction could materially improve the thesis, but future filings, regulator feedback, financing, and trial execution remain uncertain [#PR-EARNINGS-2026-07-06].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-08-13 • Updated nightlySource: Internal modelMethodology